Scalable Dean Flow microfluidic technology for low-shear lipid nanoparticle production with superior particle uniformity and linear scalability.
Lipid nanoparticle (LNP) technology has emerged as a leading delivery platform for nucleic acid therapeutics, enabling efficient intracellular delivery through well-characterized mechanisms of endosomal escape and cargo release. However, translating laboratory-scale LNP formulations to manufacturing production requires mixing technologies capable of maintaining consistent particle characteristics across scales while protecting sensitive biological payloads. Dean Flow microfluidic technology addresses these challenges through secondary flow patterns generated within curved microchannels, offering distinct advantages including reduced shear stress, minimized clogging risk, and linear scalability for commercial manufacturing. BOC Sciences provides comprehensive Dean Flow LNP production services, offering access to optimized curved-channel platforms, systematic parameter development, and scalable manufacturing capabilities that deliver consistent, high-quality LNP formulations for your therapeutic development programs.
LNP Production by Dean Flow MixingWe provide comprehensive Dean Flow microfluidic services spanning formulation development, manufacturing, scale-up, and quality control for lipid nanoparticle production. Our integrated approach ensures consistent particle quality and efficient technology transfer from laboratory to commercial scale.
We optimize lipid compositions, concentrations, and buffer systems for Dean Flow production platforms. Our formulation scientists leverage extensive experience with ionizable lipid systems to maximize encapsulation efficiency and particle stability.
We operate validated Dean Flow production platforms ranging from laboratory-scale feasibility studies to commercial manufacturing campaigns. Our manufacturing services deliver consistent particle quality and batch-to-batch reproducibility.
We provide seamless technology transfer from laboratory to production scale using validated Dean Flow scale-up strategies. Our engineering expertise ensures consistent mixing dynamics and particle characteristics across all manufacturing scales.
We provide comprehensive characterization services supporting Dean Flow production quality control. Our analytical laboratories provide complete particle characterization spanning size, morphology, encapsulation, and stability assessment.
We operate a comprehensive portfolio of Dean Flow production systems ranging from laboratory development to pilot-scale manufacturing, enabling seamless technology transfer from concept through commercialization.
Leverage curved-channel microfluidic mixing for low-shear, high-throughput LNP production. From feasibility studies to manufacturing scale.
We provide comprehensive Dean Flow LNP production services supporting diverse therapeutic applications requiring high-quality lipid nanoparticle formulations with precise control over particle characteristics.
mRNA Delivery
Delivering precise control over particle characteristics critical for mRNA delivery applications. Consistent particle size and high encapsulation efficiency support optimal transfection efficiency and immunogenicity profiles.
siRNA Gene Silencing
Supporting high-quality siRNA delivery formulations with high encapsulation efficiency that protects siRNA from nuclease degradation while maintaining particle characteristics needed for efficient cellular uptake.
Peptide and Protein Delivery
Enabling successful LNP-based peptide delivery and LNP-based protein delivery applications where payload integrity and high encapsulation efficiency are essential.
Gene Editing Components
Supporting encapsulation of gene editing payloads including CRISPR-Cas components. Controlled Dean Flow mixing minimizes shear stress on sensitive biological molecules while maintaining consistent particle quality.
Small Molecule Drug Delivery
Delivering reproducible lipid nanoparticles for drug delivery of hydrophobic small molecules using Dean Flow technology with controlled drug loading and release characteristics.
Vaccine Development
Supporting scalable Dean Flow LNP production for lipid nanoparticle for vaccine development, enabling rapid transition from laboratory through large-scale manufacturing.
Our Dean Flow LNP scale-up services enable seamless translation from laboratory development to commercial manufacturing while maintaining consistent particle quality and process performance.
| Scale Level | Dean Flow Configuration | Our Services |
|---|---|---|
| Research Scale | Single spiral or serpentine chip, 0.1-5 mL/min | Rapid feasibility assessment and parameter screening for lipid nanoparticle formulation development |
| Development Scale | Multi-bend serpentine, 5-50 mL/min | DoE-based process optimization and nanoparticle size analysis for batch production |
| Pilot Scale | Parallel channel arrays or large-radius spirals, 50-500 mL/min | Process validation and scale verification with complete documentation for technology transfer |
| Production Scale | Multi-channel parallel systems, 500 mL/min - 2 L/min | Commercial manufacturing with validated lipid nanoparticle encapsulation processes |
We provide comprehensive analytical validation ensuring Dean Flow-produced LNP batches meet specifications for all critical quality attributes.
Particle Size Analysis
We provide dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA) with validated methods for nanoparticle size analysis.
Encapsulation Efficiency
We offer fluorometric assays (RiboGreen/PicoGreen) and chromatography methods delivering accurate lipid nanoparticle encapsulation quantification.
Zeta Potential Analysis
We provide laser Doppler electrophoresis supporting nanoparticle zeta potential analysis for surface charge characterization.
Morphology Analysis
We offer Cryo-TEM and SAXS techniques providing morphology characterization for particle structure verification.
Drug Loading Analysis
We provide comprehensive drug loading analysis enabling accurate payload quantification and encapsulation efficiency determination.
Stability Assessment
We offer accelerated and long-term stability studies combined with lipid nanoparticle stability services supporting shelf-life determination.
Evaluation of payload characteristics and production requirements to determine whether Dean Flow technology offers advantages over alternative mixing platforms for your specific application.
Systematic DoE-based screening of channel geometries, flow rates, and formulation variables identifies optimal Dean Flow conditions for target particle attributes.
Execution of scale-up studies maintaining constant Dean number across production scales, with comprehensive process performance qualification and documentation.
Large-scale Dean Flow production with complete documentation package for seamless technology transfer or continued commercial supply.
Challenge: A client developing a self-amplifying mRNA (samRNA) vaccine candidate experienced significant payload degradation during formulation on a conventional staggered herringbone mixer. The large transcript size (approximately 9 kb) and complex secondary structure made it particularly sensitive to shear forces, resulting in fragmented mRNA and reduced translation efficiency.
Solution: We evaluated Dean Flow technology as an alternative production platform based on its inherently lower shear environment. We designed a systematic comparison study between the existing SHM process and a Dean Flow configuration. First, we calculated the maximum shear rate for both platforms at equivalent mixing conditions, revealing that the Dean Flow mixer produced peak shear stresses approximately 40% lower than the SHM at the same Dean number-equivalent mixing intensity. Next, we optimized the Dean Flow parameters using a serpentine channel configuration with curvature radius of 2 mm and hydraulic diameter of 200 micrometers, operating at a Dean number of 45 (flow rate 15 mL/min, FRR 1:3). We systematically varied total flow rate from 10-30 mL/min to identify the optimal balance between mixing completeness and shear minimization.
Result: The Dean Flow process achieved comparable particle quality (size 92 nm, PDI 0.09, encapsulation efficiency 89%) while preserving mRNA integrity. Capillary gel electrophoresis analysis showed intact mRNA percentage increased from 72% (SHM process) to 94% (Dean Flow process). In vitro translation assays confirmed 35% higher protein expression levels from Dean Flow-produced formulations. The client subsequently scaled the Dean Flow process to pilot production at 200 mL/min using parallel channel arrays.
Challenge: A biotechnology company required production of LNP formulations containing 20 mg/mL total lipid concentration in the organic phase—significantly higher than standard 5-10 mg/mL formulations. The elevated lipid concentration increased organic phase viscosity by approximately 3-fold, causing severe clogging and inconsistent flow on their existing staggered herringbone mixer platform after only 30 minutes of operation.
Solution: We recommended transitioning to a Dean Flow platform based on its superior tolerance for high-viscosity fluids and reduced clogging tendency from smooth channel walls. We designed a custom spiral Dean Flow mixer with curvature radius of 3 mm and rectangular channel cross-section (width 300 micrometers, height 150 micrometers, aspect ratio 2:1). The larger channel dimensions accommodated the elevated viscosity while maintaining efficient Dean vortex formation. Process optimization identified an optimal Dean number of 35 (flow rate 25 mL/min) with FRR 1:5, providing complete mixing without excessive pressure buildup. We also implemented an inline dilution strategy where the initial LNP formation occurred at high lipid concentration followed by immediate buffer dilution to reduce viscosity for downstream processing.
Result: The Dean Flow process achieved stable continuous operation for 8 hours without clogging or flow interruption. Particle size remained consistent at 105 nm (±3 nm) with PDI below 0.12 throughout the run. Encapsulation efficiency of the high-loading formulation reached 87%, comparable to lower-concentration processes. The client successfully transferred the process to their internal production facility for continued supply.
Proprietary Dean Flow PlatformOur optimized curved-channel designs maximize Dean vortex efficiency while minimizing shear stress, delivering superior particle uniformity compared to standard microfluidic systems.
Linear Scalability AdvantageTrue linear scale-up without process redesign—channel dimensions scale proportionally while maintaining identical mixing hydrodynamics from research to commercial production.
High-Viscosity Formulation CapabilityOur Dean Flow systems accommodate concentrated lipid formulations (up to 3x standard concentrations) without clogging, enabling higher payload loading and reduced volume for administration.
Sensitive Payload ProtectionLow-shear mixing environment preserves nucleic acid integrity for large transcripts (up to 9 kb) and complex gene editing components, achieving 40% lower peak shear than conventional mixers.
Integrated Production CapabilityEnd-to-end services from formulation development through commercial manufacturing, including downstream processing, analytical characterization, and complete technology transfer documentation.
Dean flow technology utilizes secondary flows (Dean vortices) generated within curved microchannels to achieve efficient mixing, which is its core mechanism distinguishing it from conventional staggered herringbone micromixers. Dean vortices form counter-rotating vortex pairs within the channel cross-section, significantly accelerating mixing without relying on complex surface structures. Unique advantages of Dean flow technology include: linear scalability—channel dimensions can be proportionally scaled while maintaining identical mixing characteristics, eliminating the need for channel parallelization required by conventional microfluidics; larger channel dimensions result in lower clogging risk; and mixing time has weak correlation with flow rate, facilitating true linear scale-up. BOC Sciences provides complete Dean flow LNP production platforms enabling seamless process transfer from laboratory to production scale.
Dean number (De) is a dimensionless parameter characterizing the intensity of secondary flows in curved channels, calculated from Reynolds number and channel curvature ratio. Dean number directly determines mixing intensity and fluid shear environment, being a critical process parameter affecting LNP particle size characteristics. Generally, increasing Dean number within a certain range enhances mixing intensity, producing smaller and more uniform nanoparticles; however, excessively high Dean numbers may cause excessive shear forces affecting sensitive nucleic acid payload integrity or altering lipid structure. Establishing Dean number-particle size response curves through systematic DoE experiments enables determination of optimal Dean number operating windows for specific formulation systems. BOC Sciences process development team has accumulated extensive experience in Dean number optimization, enabling rapid establishment of robust process parameters for clients.
The secondary flow mixing mechanism of Dean flow technology demonstrates good adaptability when processing various lipid formulations. Standard mRNA lipid formulations (ionizable lipids, cholesterol, DSPC, PEG-lipid) achieve uniform particle size distribution and efficient encapsulation on Dean flow platforms. For high-concentration lipid formulations (total lipid concentration exceeding 10 mg/mL), Dean flow technology outperforms conventional microfluidics because larger channel dimensions and unique vortex patterns effectively address mass transfer challenges from high viscosity. For formulations containing sensitive functional lipids (such as pH-sensitive dye-labeled lipids), Dean flow enables fine Dean number adjustment to balance mixing efficiency and lipid integrity. BOC Sciences can assist clients in evaluating Dean flow technology applicability for their specific formulations.
A core advantage of Dean flow technology is its inherent linear scalability. Scale-up strategies primarily include two approaches: geometric amplification—increasing channel equivalent diameter and hydraulic radius while proportionally adjusting flow rates to maintain constant Dean number; and channel parallelization—operating multiple identical Dean flow chips simultaneously to increase total throughput. During geometric amplification, maintaining constant Dean number and Froude number ensures mixing kinetic consistency. BOC Sciences has established a complete scale-up platform spanning from laboratory scale (single channel) to pilot scale (channel arrays) and then to production scale (industrial modules), providing validated scale-up factors and comprehensive process transfer documentation support.
Common issues in Dean flow LNP production include: large particle size or broad distribution, which may relate to low Dean number settings or insufficient mixing length—solutions include optimizing Dean number and total channel length; abnormal pressure increase, typically caused by high viscosity from high-concentration formulations or channel wall contamination—solutions include pre-heating to reduce viscosity or performing online cleaning; and bubble interference, as secondary flows have capture effects on bubbles—solutions include degassing solutions before feeding and optimizing chip orientation to facilitate bubble removal. BOC Sciences provides comprehensive Dean flow process support including problem diagnosis, process optimization guidance, and thorough operational training, helping clients establish stable production processes.
